
    
      This is a one-period, double-blind, single-center pharmacokinetic study of linezolid in
      patients with MDR or XDR tuberculosis treated with linezolid and an Optimized Background
      Therapy (defined as treatment with > 4 drugs with activity against tuberculosis to which the
      patient's isolate is believed to be sensitive by history or based on drug sensitivity
      testing).
    
  